Lung Cancer Surgery Can Be Beneficial for High-Risk Patients with Early Stage Disease

A multidisciplinary approach is necessary to determine best treatment for each patient

Chicago, 10 November 2015

Surgical lung resection, in which part of a lung is removed, can be a safe and effective treatment option for high-risk patients with early stage lung cancer, according to an article posted online by The Annals of Thoracic Surgery.  

Key Points:

  • Surgical lung resection can safely be used as a treatment option with good results for patients with lung cancer who have been identified as high-risk for surgery.
  • Overall length of hospital stay was longer for high-risk patients compared to standard-risk patients, but there was no difference among the two groups in post-operative mortality.
  • The researchers emphasize the importance of a multidisciplinary approach to determine the best treatment plan for each individual lung cancer patient.

Previous research has shown that most patients with lung cancer who undergo pulmonary resection are age 60 years or older, have a significant smoking history, and have numerous other conditions—such as lung disease or heart disease—that could lead to higher rates of complications or death following lung surgery.

“Consequently, one in five patients with stage I non–small-cell lung cancer is deemed inoperable or at high-risk for surgery,” said Manu S. Sancheti, MD, from Emory University in Atlanta. “Our research shows these patients should not be denied surgery, because they may benefit from it.”

Dr. Sancheti led a research team that identified 490 patients who underwent surgical resection for early stage lung cancer at Emory from 2009 through 2013. Patients were classified as standard risk (310 patients) or high risk (180 patients), based on previously published criteria from the American College of Surgery Oncology Group.

The researchers evaluated patient outcomes and survival following surgery and found that overall length of hospital stay was longer for high-risk patients (5 days) compared to standard-risk patients (4 days), but there was no difference among the two groups in post-operative mortality (2% for high-risk patients; 1% for standard-risk patients).

“Importantly, we found that about 20% of our patients had cancer that had spread to their lymph nodes, a finding that was unexpected based on the pre-operative imaging tests,” said Dr. Sancheti. “This group of patients was able to undergo chemotherapy, which is an important adjunct treatment for their cancer stage. This spread of cancer to the lymph nodes would not have been discovered and accordingly treated through a non-surgical approach.” 

At 3-years post-surgery, the researchers found that 59% of high-risk patients were still alive, and 76% of standard-risk patients had survived.

“Our results show that surgical resection is an acceptable treatment option with good results for patients with early stage lung cancer who have been identified as high-risk for surgery,” said Dr. Sancheti. “High-risk patients have a new treatment avenue that previously may have been denied to them. A multidisciplinary team should review each case to determine the best treatment plan for individual lung cancer patients.”


Notes for editors
Sancheti M, Melvan J, Medbery R, Fernandez F, Gillespie T, Li Q, Binongo J, Pickens A, Force S. Outcomes After Surgery In High-Risk Patients With Early Stage Lung Cancer. Ann Thoracic Surg 2015; DOI: 10.1016/j.athoracsur.2015.08.088

Note: No authors reported any disclosures 

Full text of the article is available to credentialed journalists upon request; contact Cassie McNulty at +1 312 202 5865.

About The Annals of Thoracic Surgery 
The Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association. Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,800 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Cassie McNulty
Media Relations Manager STS
+1 312 202 5865